ICH Q3B Impurities in New Drug Products

Target entity: ICH Q3B Impurities in New Drug Products
Context triple: [ICH Q3A Impurities in New Drug Substances, relatedGuideline, ICH Q3B Impurities in New Drug Products]

• A. ICH Q3A Impurities in New Drug Substances
  ICH Q3A Impurities in New Drug Substances is an international regulatory guideline that sets quality standards and thresholds for identifying, reporting, and controlling impurities in new active pharmaceutical ingredients.
• B. ICH Q11 Development and Manufacture of Drug Substances
  ICH Q11 Development and Manufacture of Drug Substances is an ICH guideline that provides principles and expectations for the development and manufacturing of chemical and biotechnological drug substances within a quality-by-design framework.
• C. ICH Q1 Stability Testing of New Drug Substances and Products
  ICH Q1 Stability Testing of New Drug Substances and Products is an international regulatory guideline that defines the scientific principles and study requirements for assessing the stability, shelf life, and storage conditions of new pharmaceutical substances and finished products.
• D. ICH Q8 Pharmaceutical Development
  ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
• E. ICH Q10 Pharmaceutical Quality System
  ICH Q10 Pharmaceutical Quality System is an international guideline that establishes a comprehensive, lifecycle-based framework for pharmaceutical quality management to ensure consistent product quality and regulatory compliance.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: ICH Q3B Impurities in New Drug Products
Target entity description: ICH Q3B Impurities in New Drug Products is an ICH quality guideline that sets thresholds and requirements for identifying, reporting, and qualifying impurities present in finished pharmaceutical products.

• A. ICH Q3A Impurities in New Drug Substances
  ICH Q3A Impurities in New Drug Substances is an international regulatory guideline that sets quality standards and thresholds for identifying, reporting, and controlling impurities in new active pharmaceutical ingredients.
• B. ICH Q11 Development and Manufacture of Drug Substances
  ICH Q11 Development and Manufacture of Drug Substances is an ICH guideline that provides principles and expectations for the development and manufacturing of chemical and biotechnological drug substances within a quality-by-design framework.
• C. ICH Q1 Stability Testing of New Drug Substances and Products
  ICH Q1 Stability Testing of New Drug Substances and Products is an international regulatory guideline that defines the scientific principles and study requirements for assessing the stability, shelf life, and storage conditions of new pharmaceutical substances and finished products.
• D. ICH Q8 Pharmaceutical Development
  ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
• E. ICH Q10 Pharmaceutical Quality System
  ICH Q10 Pharmaceutical Quality System is an international guideline that establishes a comprehensive, lifecycle-based framework for pharmaceutical quality management to ensure consistent product quality and regulatory compliance.
• F. None of above. chosen